Meeting
2021 ASCO Annual Meeting
Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck.
Authors
Glenn J. Hanna
Dana-Farber Cancer Institute, Boston, MA
Glenn J. Hanna , Anne M. O'Neill , Vickie Y. Jo , Kristine Wong , Patrick H. Lizotte , Donald J. Annino Jr., Laura A. Goguen , Jason I. Kass , Eleni M. Rettig , Rosh K.V. Sethi , Jochen H. Lorch , Jonathan D. Schoenfeld , Danielle N. Margalit , Roy B. Tishler , Peter C. Everett , Anupam M. Desai , Cloud P. Paweletz , Ann Marie Egloff , Ravindra Uppaluri , Robert I. Haddad
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT03341936
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 6053)
DOI
10.1200/JCO.2021.39.15_suppl.6053
Abstract #
6053
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Multicenter randomized controlled phase III study of nivolumab alone or in combination with ipilimumab as immunotherapy vs standard follow-up in surgical resectable HNSCC after adjuvant therapy.
First Author: Chia-Jung Busch
Poster
2023 ASCO Annual Meeting
A pilot phase II trial of neoadjuvant camrelizumab plus nab-paclitaxel and cisplatin (NeoCPC) for locoregionally advanced, resectable squamous cell carcinoma of the head and neck.
First Author: Di Wu
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase II study to evaluate anlotinib plus TQB2450 as adjuvant therapy in patients with esophageal squamous cell carcinoma (ALTER-E005).
First Author: Changying Guo
Poster
2019 ASCO Annual Meeting
Feasibility and toxicity of neoadjuvant nivolumab with or without ipilimumab prior to extensive (salvage) surgery in patients with advanced head and neck cancer (the IMCISION trial, NCT03003637).
First Author: Charlotte L. Zuur